Endocyte, Inc. Logo

Image Following Treatment with 177Lu-PSMA-617 Selected by Society of Nuclear Medicine and Molecular Imaging as Image of the Year

June 26, 2018

Image depicts PSMA PET scans of eight patients with exceptional responses from investigator-sponsored Phase 2 study

WEST LAFAYETTE, Ind., June 26, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that an image from a Phase 2 study of ^{177}Lu-PSMA-617, led by Dr. Michael Hofman of the Peter McCallum Cancer Centre in Melbourne, Australia, was selected at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting as the “Image of the Year.” The image depicts the positron emissions tomography (PET) scans of eight patients before treatment with ^{177}Lu-PSMA-617 and at three months following treatment.

SNMMI Image of the Year: 68Ga-PSMA-11 PET maximum intensity projection (MIP) images at baseline and three months after 177Lu-PSMA-617 in eight patients with PSA decline 98 percent.

SNMMI Image of the Year: 68Ga-PSMA-11 PET maximum intensity projection (MIP) images at baseline and three months after 177Lu-PSMA-617 in eight patients with PSA decline > 98 percent.

“This recognition reflects the potential of ^{177}Lu-PSMA-617 and radioligand therapies to be a new treatment modality for patients with metastatic castration-resistant prostate cancer (mCRPC).” said Mike Sherman president and CEO of Endocyte. “We are grateful to SNMMI for this award and to Dr. Michael Hofman for his work with ^{177}Lu-PSMA-617. We are continuing to enroll patients with mCRPC in the Phase 3 VISION trial to confirm the promising results seen in earlier trials.”

Dr. Hofman, a clinical investigator in the study, said, “recognition of this image as Image of the Year underscores the potential impact that targeting ^{177}Lu to PSMA-positive disease has had in these patients. This recognition encourages us to continue our research at Peter MacCallum Cancer Centre in a 50-patient single arm Phase 2 study and the 200 patient TheraP Phase 2 study.”

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a721f857-695c-47cb-bca2-93615ac49880

Website Information

Endocyte routinely posts important information for investors on its website, www.endocyte.com, in the “Investors & News” section. Endocyte uses this website as a means of disclosing material information in compliance with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the “Investors & News” section of Endocyte’s website, in addition to following its press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Endocyte’s website is not incorporated by reference into, and is not a part of, this document.

About Endocyte

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, ^{177}Lu-PSMA-617, in phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic in 2018, where it will be studied in osteosarcoma. For additional information, please visit Endocyte's website at www.endocyte.com.

Forward Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the company's future development plans including those relating to the completion of pre-clinical development in preparation for possible future clinical trials, the anticipated initiation of a registration trial, and preparation for potential commercialization. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks that the company or independent investigators may experience delays in the initiation or completion of clinical trials (whether caused by competition, adverse events, patient enrollment rates, shortage of clinical trial materials, regulatory issues or other factors); risks that data from prior clinical trials may not be indicative of subsequent clinical trial results;

risks related to the safety and efficacy of the company's product candidates; risks that early stage pre-clinical data may not be indicative of subsequent data when expanded to additional pre-clinical models or to subsequent clinical data; risks that evolving competitive activity and intellectual property landscape may impair the company'sability to capture value for thetechnology; risks that expectations and estimates turn out to be incorrect, including estimates of the potential markets for the company's product candidates, estimates of the capacity of manufacturing and other facilities required to support its product candidates, projected cash needs, and expected future revenues, operations, expenditures and cash position. More information about the risks and uncertainties faced by Endocyte, Inc. is contained in the company's periodic reports filed with the Securities and Exchange Commission. Endocyte, Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:
Michael Schaffzin, Stern Investor Relations, Inc., (212) 362-1200, michael@sternir.com


Primary Logo

Source: Endocyte, Inc.